Literature DB >> 16835693

The German Competence Net Dementias: standard operating procedures for the neurochemical dementia diagnostics.

P Lewczuk1, J Kornhuber, J Wiltfang.   

Abstract

Aging of population results in an increasing number of patients with dementia. Therefore, recently a BMBF-supported project, Competence Net Dementia, was launched to reveal diagnostic, therapeutic, and epidemiologic aspects of demential disorders. In this project, our task was to establish and maintain human body fluids (HBF) bank to collect cerebrospinal fluid, plasma, serum, and full blood of patients enrolled into the study. As the pre-analytical sample handling is a prerequisite of all studies aiming at finding novel disease biomarkers, standard operating procedures (SOPs) were launched by our group to allow standardized collection, storage, and shipment of the samples among all 14 University centers involved in HBF collection. Currently, to our best knowledge the CND HBF bank represents one of the largest prospectively collected set of the samples from subjects with mild cognitive impairment and early dementias. With the samples collected in the HBF bank, recently introduced analytical technologies (like e.g. surface enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS), differential gel electrophoresis (DIGE), and multiplexing) can be promptly tested with regard to their potential usefulness in neurochemical dementia diagnostics.

Entities:  

Mesh:

Year:  2006        PMID: 16835693     DOI: 10.1007/s00702-006-0511-9

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  14 in total

1.  Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease.

Authors:  N Andreasen; C Hesse; P Davidsson; L Minthon; A Wallin; B Winblad; H Vanderstichele; E Vanmechelen; K Blennow
Journal:  Arch Neurol       Date:  1999-06

Review 2.  Recent advancements in surface-enhanced laser desorption/ionization-time of flight-mass spectrometry.

Authors:  M Merchant; S R Weinberger
Journal:  Electrophoresis       Date:  2000-04       Impact factor: 3.535

Review 3.  New drugs for Alzheimer's disease and other dementias.

Authors:  Roger Bullock
Journal:  Br J Psychiatry       Date:  2002-02       Impact factor: 9.319

4.  Effect of sample collection tubes on cerebrospinal fluid concentrations of tau proteins and amyloid beta peptides.

Authors:  Piotr Lewczuk; Georg Beck; Hermann Esselmann; Ralf Bruckmoser; Rüdiger Zimmermann; Magdalena Fiszer; Mirko Bibl; Juan Manuel Maler; Johannes Kornhuber; Jens Wiltfang
Journal:  Clin Chem       Date:  2006-02       Impact factor: 8.327

Review 5.  Consensus report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease". The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group.

Authors: 
Journal:  Neurobiol Aging       Date:  1998 Mar-Apr       Impact factor: 4.673

Review 6.  Evaluation and use of diagnostic tests in Alzheimer's disease.

Authors:  R Mayeux
Journal:  Neurobiol Aging       Date:  1998 Mar-Apr       Impact factor: 4.673

7.  Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice.

Authors:  N Andreasen; L Minthon; P Davidsson; E Vanmechelen; H Vanderstichele; B Winblad; K Blennow
Journal:  Arch Neurol       Date:  2001-03

8.  Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology.

Authors:  Annika Olsson; Hugo Vanderstichele; Niels Andreasen; Geert De Meyer; Anders Wallin; Björn Holmberg; Lars Rosengren; Eugeen Vanmechelen; Kaj Blennow
Journal:  Clin Chem       Date:  2004-11-24       Impact factor: 8.327

9.  Determining a significant change in protein expression with DeCyder during a pair-wise comparison using two-dimensional difference gel electrophoresis.

Authors:  Natasha A Karp; David P Kreil; Kathryn S Lilley
Journal:  Proteomics       Date:  2004-05       Impact factor: 3.984

10.  The amyloid-beta (Abeta) peptide pattern in cerebrospinal fluid in Alzheimer's disease: evidence of a novel carboxyterminally elongated Abeta peptide.

Authors:  Piotr Lewczuk; Hermann Esselmann; Markus Meyer; Volker Wollscheid; Manuela Neumann; Markus Otto; Juan Manuel Maler; Eckart Rüther; Johannes Kornhuber; Jens Wiltfang
Journal:  Rapid Commun Mass Spectrom       Date:  2003       Impact factor: 2.419

View more
  20 in total

1.  Biomarkers of neurodegeneration - not only Alzheimer's disease and not only cerebrospinal fluid: a guest-editor's introduction.

Authors:  Piotr Lewczuk
Journal:  J Neural Transm (Vienna)       Date:  2012-07       Impact factor: 3.575

2.  Evolution of Abeta42 and Abeta40 levels and Abeta42/Abeta40 ratio in plasma during progression of Alzheimer's disease: a multicenter assessment.

Authors:  K Blennow; G De Meyer; O Hansson; L Minthon; A Wallin; H Zetterberg; P Lewczuk; H Vanderstichele; E Vanmechelen; J Kornhuber; J Wiltfang; I Heuser; W Maier; C Luckhaus; E Rüther; M Hüll; H Jahn; H J Gertz; L Frölich; H Hampel; R Pernetzki
Journal:  J Nutr Health Aging       Date:  2009-03       Impact factor: 4.075

3.  Cognitive subtypes of probable Alzheimer's disease robustly identified in four cohorts.

Authors:  Nienke M E Scheltens; Betty M Tijms; Teddy Koene; Frederik Barkhof; Charlotte E Teunissen; Steffen Wolfsgruber; Michael Wagner; Johannes Kornhuber; Oliver Peters; Brendan I Cohn-Sheehy; Gil D Rabinovici; Bruce L Miller; Joel H Kramer; Philip Scheltens; Wiesje M van der Flier
Journal:  Alzheimers Dement       Date:  2017-04-17       Impact factor: 21.566

4.  Impact of white matter hyperintensity location on depressive symptoms in memory-clinic patients: a lesion–symptom mapping study

Authors:  Anna E. Leeuwis; Nick A. Weaver; J. Matthijs Biesbroek; Lieza G. Exalto; Hugo J. Kuijf; Astrid M. Hooghiemstra; Niels D. Prins; Philip Scheltens; Frederik Barkhof; Wiesje M. van der Flier; Geert Jan Biessels
Journal:  J Psychiatry Neurosci       Date:  2019-07-01       Impact factor: 6.186

5.  Multidimensional plasma protein separation technique for identification of potential Alzheimer's disease plasma biomarkers: a pilot study.

Authors:  Andreas Wolfram Henkel; Katharina Müller; Piotr Lewczuk; Thorsten Müller; Katrin Marcus; Johannes Kornhuber; Jens Wiltfang
Journal:  J Neural Transm (Vienna)       Date:  2012-03-14       Impact factor: 3.575

6.  Guidelines for the standardized collection of blood-based biomarkers in psychiatry: Steps for laboratory validity - a consensus of the Biomarkers Task Force from the WFSBP.

Authors:  Ana C Andreazza; Isabelle Laksono; Brisa S Fernandes; Catherine Toben; Piotr Lewczuk; Peter Riederer; Sidney H Kennedy; Dimitrios Kapogiannis; Florence Thibaut; Manfred Gerlach; Carla Gallo; Yong-Ku Kim; Edna Grünblatt; Lakshmi Yatham; Michael Berk; Bernhard T Baune
Journal:  World J Biol Psychiatry       Date:  2019-03-25       Impact factor: 4.132

Review 7.  Neurochemical dementia diagnostics: assays in CSF and blood.

Authors:  Piotr Lewczuk; Joachim Hornegger; Rüdiger Zimmermann; Markus Otto; Jens Wiltfang; Johannes Kornhuber
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-11       Impact factor: 5.270

8.  Lessons from Multicenter Studies on CSF Biomarkers for Alzheimer's Disease.

Authors:  Niklas Mattsson; Henrik Zetterberg; Kaj Blennow
Journal:  Int J Alzheimers Dis       Date:  2010-07-08

9.  Validation of the Erlangen Score Algorithm for the Prediction of the Development of Dementia due to Alzheimer's Disease in Pre-Dementia Subjects.

Authors:  Piotr Lewczuk; Johannes Kornhuber; Jon B Toledo; John Q Trojanowski; Malgorzata Knapik-Czajka; Oliver Peters; Jens Wiltfang; Leslie M Shaw
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

Review 10.  Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry.

Authors:  Piotr Lewczuk; Peter Riederer; Sid E O'Bryant; Marcel M Verbeek; Bruno Dubois; Pieter Jelle Visser; Kurt A Jellinger; Sebastiaan Engelborghs; Alfredo Ramirez; Lucilla Parnetti; Clifford R Jack; Charlotte E Teunissen; Harald Hampel; Alberto Lleó; Frank Jessen; Lidia Glodzik; Mony J de Leon; Anne M Fagan; José Luis Molinuevo; Willemijn J Jansen; Bengt Winblad; Leslie M Shaw; Ulf Andreasson; Markus Otto; Brit Mollenhauer; Jens Wiltfang; Martin R Turner; Inga Zerr; Ron Handels; Alexander G Thompson; Gunilla Johansson; Natalia Ermann; John Q Trojanowski; Ilker Karaca; Holger Wagner; Patrick Oeckl; Linda van Waalwijk van Doorn; Maria Bjerke; Dimitrios Kapogiannis; H Bea Kuiperij; Lucia Farotti; Yi Li; Brian A Gordon; Stéphane Epelbaum; Stephanie J B Vos; Catharina J M Klijn; William E Van Nostrand; Carolina Minguillon; Matthias Schmitz; Carla Gallo; Andrea Lopez Mato; Florence Thibaut; Simone Lista; Daniel Alcolea; Henrik Zetterberg; Kaj Blennow; Johannes Kornhuber
Journal:  World J Biol Psychiatry       Date:  2017-10-27       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.